MDV3100 for the treatment of prostate cancer

Bibliography

• Jemal A, Siegel R, XU J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(2):277-300
   PubMedGoogle Scholar
• La Vecchia C, Bosetti C, Lucchini F, Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010;21(6):1323-60
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O'Sullivan JM, Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA), in European Multidsiciplinary Cancer Congress 2011. Stockholm: European Journal of Cancer Volume 47 Supplement 2, September 2011
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• MEDIVATION. Medivation and Astellas Announce Positive Survival Data From Interim Analysis of Phase 3 AFFIRM Trial of MDV3100 in Men With Advanced Prostate Cancer. 2011. Available from: http://investors.medivation.com/releasedetail.cfm?ReleaseID=620500 [Cited 03 November 2011]
   Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168(1):9-12
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948-51; discussion 952
   PubMed Web of Science ®Google Scholar
• Peeling WB. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate. Prog Clin Biol Res 1989;303:41-5
   PubMedGoogle Scholar
• Soloway MS, Chodak G, Vogelzang NJ, Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology 1991;37(1):46-51
   PubMed Web of Science ®Google Scholar
• Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96(9):1241-6
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217-27
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, Ford OH 3rd, The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440-8
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW, Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-41
   PubMed Web of Science ®Google Scholar
• Page ST, Lin DW, Mostaghel EA, Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91(10):3850-6
   PubMed Web of Science ®Google Scholar
• Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009;115(15):3376-8
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Usami M, Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115(15):3437-45
   PubMed Web of Science ®Google Scholar
• Sartor AO, Tangen CM, Hussain MH, Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112(11):2393-400
   PubMed Web of Science ®Google Scholar
• Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34(1):61-72
   PubMed Web of Science ®Google Scholar
• Taplin ME, Bubley GJ, Shuster TD, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-8
   PubMed Web of Science ®Google Scholar
• Smith DC, Redman BG, Flaherty LE, A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52(2):257-60
   PubMed Web of Science ®Google Scholar
• Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002;1(2):81-9
   PubMedGoogle Scholar
• Small EJ, Halabi S, Dawson NA, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33
   PubMed Web of Science ®Google Scholar
• Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23(32):8247-52
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010;363(5):479-81
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5(11):610-20
   PubMedGoogle Scholar
• Teutsch G, Goubet F, Battmann T, Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 1994;48(1):111-19
   PubMed Web of Science ®Google Scholar
• Van Dort ME, Robins DM, Wayburn B. Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. J Med Chem 2000;43(17):3344-7
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
   PubMed Web of Science ®Google Scholar
• Higano CBT, Yu E, Taplin ME, Phase 1-2 study of MDV3100 in pre- and post-docetaxel advanced prostate cancer: long-term efficacy results. J Urol 2011;185(4 Suppl):abstract 647
   Google Scholar
• de Bono JS, Scher HI, Montgomery RB, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14(19):6302-9
   PubMed Web of Science ®Google Scholar
• Olmos D, Arkenau T, Ang LE, Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20(1):27-33
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, de Bono JS, Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10(3):233-9
   PubMed Web of Science ®Google Scholar
• Scher HI, Heller G, Molina AS, Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011;29(Suppl):LBA4517
   Google Scholar
• Cai C, Chen S, Ng P, Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71(20):6503-13
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17(18):5913-25
   PubMed Web of Science ®Google Scholar
• Watson PA, Chen YF, Balbas MD, Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010;107(39):16759-65
   PubMed Web of Science ®Google Scholar